Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/355200
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampTambascia, Marcos Antonio-
dc.typeArtigopt_BR
dc.titleDegludec: the new ultra-long insulin analoguept_BR
dc.contributor.authorTambascia, Marcos Antonio-
dc.contributor.authorEliaschewitz, Freddy Goldberg-
dc.subjectHipoglicemiapt_BR
dc.subjectFarmacocinéticapt_BR
dc.subject.otherlanguageHypoglycemiapt_BR
dc.subject.otherlanguagePharmacokineticspt_BR
dc.description.abstractThe development of extended-action insulin analogues was motivated by the unfavorable pharmacokinetic (PK) profile of the conventional long-acting insulin formulations, generally associated with marked inter and intra patient variability and site-and dose-dependent effect variation. The new ultra-long insulin analogue degludec (IDeg) has the same amino acid sequence as human insulin except for the removal of threonine in the position 30 of the B chain (Des-B30, "De") and the attachment, via a glutamic acid linker ("glu"), of a 16-carbon fatty diacid (hexadecanoic diacid, "dec") to lysine in the position 29 of the B chain. These modifications allow that, after changing from the pharmaceutical formulation to the subcutaneous environment, IDeg precipitates in the subcutaneous tissue, forming a depot that undergoes a highly predictable gradual dissociation. Thus, once-daily dosing of IDeg results in a low peak: trough ratio, with consequent low intra-individual variability and plasmatic concentrations less critically dependent upon the time of injections. The clinical development program of IDeg (BEGIN) was comprised of 9 therapeutic confirmatory trials of longer duration (26-52 weeks) and showed that the efficacy of IDeg is comparable to insulin glargine in type 1 (T1D) and type 2 (T2D) diabetes patients across different age, body mass index and ethnic groups. This new ultra-long insulin analogue presents as advantages flexibility in dose timing and lower risk of hypoglycemiapt_BR
dc.relation.ispartofDiabetology & metabolic syndromept_BR
dc.relation.ispartofabbreviationDMSpt_BR
dc.publisher.cityLondonpt_BR
dc.publisher.countryReino Unidopt_BR
dc.publisherBioMed Centralpt_BR
dc.date.issued2015-
dc.date.monthofcirculationJunept_BR
dc.language.isoengpt_BR
dc.description.volume7pt_BR
dc.rightsFechadopt_BR
dc.sourceWOSpt_BR
dc.identifier.eissn1758-5996pt_BR
dc.identifier.doi10.1186/s13098-015-0037-0pt_BR
dc.identifier.urlhttps://dmsjournal.biomedcentral.com/articles/10.1186/s13098-015-0037-0pt_BR
dc.date.available2021-02-03T14:47:13Z-
dc.date.accessioned2021-02-03T14:47:13Z-
dc.description.provenanceSubmitted by Cintia Oliveira de Moura (cintiaom@unicamp.br) on 2021-02-03T14:47:13Z No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2021-02-03T14:47:13Z (GMT). No. of bitstreams: 0 Previous issue date: 2015en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/355200-
dc.contributor.departmentDepartamento de Clínica Médicapt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.identifier.source000357072300001pt_BR
dc.creator.orcid0000-0002-9158-6902pt_BR
dc.type.formArtigo de revisãopt_BR
dc.identifier.articleid57pt_BR
dc.description.sponsorNoteNovo Nordiskpt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.